Director Richard J. Daly filed a Form 4 with the SEC on November 10, 2026, disclosing the acquisition of a non-qualified stock option to purchase 57,000 shares of Aquestive Therapeutics, Inc. common stock, with the transaction dated November 6, 2026.

Key Highlights

  • Reporting person: Richard J. Daly, identified as a Director of Aquestive Therapeutics, Inc.
  • Security acquired: Non-qualified stock option (right to buy) covering 57,000 shares of common stock
  • Exercise price: $3.61 per share
  • Transaction date: November 6, 2026, with a transaction code of "A" (acquired)
  • Price paid: $0 for the option grant
  • Expiration date: November 6, 2036
  • Vesting schedule: The option vests in three equal annual installments beginning on November 6, 2027

Aquestive Therapeutics Director Receives Option Grant Vesting Over Three Years

According to the Form 4 filed on November 10, 2026, Richard J. Daly, a director of Aquestive Therapeutics, Inc. (NASDAQ:AQST), acquired a non-qualified stock option to purchase 57,000 shares of the company's common stock. The transaction was dated November 6, 2026, and the option was obtained at no cost, with a price of $0 reported for the derivative security itself.

The filing discloses that the exercise price of the option is $3.61 per share and that the option expires on November 6, 2036. As noted in the explanation of responses, "The option vests in three equal annual installments beginning on November 6, 2027." Following this transaction, the filing reports that Daly directly and beneficially owns 57,000 derivative securities of this type.

No non-derivative securities transactions were reported in Table I of the filing. The form was signed by Thomas Zalewski as Attorney-In-Fact on November 10, 2026, and was filed as an individual, single-reporting-person disclosure. No amendment date was listed, indicating this is an original filing.

What Was Disclosed

The filing reports a single grant of a non-qualified stock option covering 57,000 shares of Aquestive Therapeutics common stock to Director Richard J. Daly on November 6, 2026, at an exercise price of $3.61 per share, expiring November 6, 2036, with vesting in three equal annual installments starting November 6, 2027.